Skip to main content

Advertisement

SpringerLink
Log in

EANM procedure guidelines for therapy of benign thyroid disease

  • Guidelines
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

The purpose of the present guidelines on the 131I therapy of benign thyroid disorders formulated by the European Association of Nuclear Medicine (EANM) Therapy Committee is to provide advice to nuclear medicine clinicians on how to treat benign thyroid conditions employing optimal 131I activities. The recommendations were formulated based on recent literature and expert opinion regarding rationale, indications and contraindications for the use of 131I procedures, as well as the adequate 131I activities in different thyroid disorders, and the administration and patient preparation techniques to be used. Recommendations are also provided on history and examinations before 131I therapy, patient counselling and precautions associated with 131I therapy. Furthermore, potential side effects and alternative treatment modalities are reviewed. Special attention is paid to these aspects in the treatment of children undergoing this procedure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McDermott MT, Woodmansee WW, Haugen BR, et al. The management of subclinical hyperthyroidism by thyroid specialists. Thyroid. 2003;13:1133–9.

    Article  PubMed  Google Scholar 

  2. Freitas JE. Therapeutic options in the management of toxic and nontoxic nodular goiter. Semin Nucl Med. 2000;30:88–97.

    Article  PubMed  CAS  Google Scholar 

  3. Reinwein D, Benker G, Lazarus JH, Alexander WD, the European multicenter study group on antithyroid drug treatment. A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. J Clin Endocrinol Metab. 1993;76:1516–21.

    Article  PubMed  CAS  Google Scholar 

  4. Fast S, Nielsen V, Bonnema S, Hegedus L. Time to reconsider nonsurgical therapy of benign nontoxic multinodular goitre. Focus on recombinant human TSH (rhTSH) augmented radioiodine therapy. Eur J Endocrinol. 2008;160:517–28.

    Article  PubMed  CAS  Google Scholar 

  5. Papini E, Petrucci L, Guglielmi R, Panunzi C, Rinaldi R, Bacci V, et al. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab. 1998;83:780–3.

    Article  PubMed  CAS  Google Scholar 

  6. Wesche MF, Tiel-V Buul MM, Lips P, Smits NJ, Wiersinga WM. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab. 2001;86:998–1005.

    Article  PubMed  CAS  Google Scholar 

  7. Brunn J, Block U, Ruf G, Bos I, Kunze WP, Scriba PC. Volumetric analysis of thyroid lobes by real-time ultrasound. Dtsch Med Wschr. 1981;106:1338–40.

    Article  PubMed  CAS  Google Scholar 

  8. Moschetta M, Ianora AA, Testini M, Vacca M, Scardapane A, Angelelli G. Multidetector computed tomography in the preoperative evaluation of retrosternal goiters: a useful procedure for patients for whom magnetic resonance imaging is contraindicated. Thyroid. 2010;20:181–7.

    Article  PubMed  Google Scholar 

  9. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.

    Article  PubMed  Google Scholar 

  10. Moka D, Dietlein M, Schicha H. Radioiodine therapy and thyrostatic drugs and iodine. Eur J Nucl Med Mol Imaging. 2002;29 Suppl 2:S486–91.

    Article  PubMed  CAS  Google Scholar 

  11. Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves’ disease. Thyroid. 2004;14:525–30.

    Article  PubMed  CAS  Google Scholar 

  12. Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L. Propylthiouracil before I-131 therapy of hyperthyroid diseases; effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab. 2004;89:4439–44.

    Article  PubMed  CAS  Google Scholar 

  13. Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves’ hyperthyroidism: a randomized clinical trial. Thyroid. 2002;12:135–9.

    Article  PubMed  CAS  Google Scholar 

  14. Kobe C, Weber I, Eschner W, Sudbrock F, Schmidt M, Dietlein M, et al. Graves’ disease and radioiodine therapy: is success of ablation dependent on the choice of thyreostatic medication? Nuklearmedizin. 2008;47:153–66.

    PubMed  CAS  Google Scholar 

  15. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273–85.

    Article  PubMed  CAS  Google Scholar 

  16. Bonnema SJ, Bartelana L, Toft AD, Hegedus L. Controversies in radioiodine therapy: relation to ophthalmopathy the possible radioprotective effect of antithyroid drugs, and use in large goitres. Eur J Endocrinol. 2002;147:1–11.

    Article  PubMed  CAS  Google Scholar 

  17. Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Practice Res Clin Endocrinol Metab. 2009;23:735–51.

    Article  CAS  Google Scholar 

  18. Bogazzi F, Bartalena L, Brogioni S, Scarcello G, Burelli A, Compomori A, et al. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves’ hyperthyroidism. J Clin Endocrinol Metab. 1999;84:499–530.

    Article  PubMed  CAS  Google Scholar 

  19. Bal CS, Kumar A, Pandey RM. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid. 2002;12:399–405.

    Article  PubMed  CAS  Google Scholar 

  20. Bogazzi F, Bartalena L, Compomori A, Brogioni S, Traino C, DeMartino F, et al. Treatment with Lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves’ disease. J Clin Endocrinol Metab. 2002;87:4490–5.

    Article  PubMed  CAS  Google Scholar 

  21. Silva MN, Rubió IG, Romão R, Gebrin EM, Buchpiguel C, Tomimori E, et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin Endocrinol (Oxf). 2004;60:300–8.

    Article  CAS  Google Scholar 

  22. Fast S, Nielsen VE, Grupe P, Bonnema SJ, Hegedüs L. Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study. J Nucl Med. 2009;50:732–7.

    Article  PubMed  CAS  Google Scholar 

  23. Nielsen VE, Bonnema SJ, Hegedus L. Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign non-toxic nodular goiter: a randomized, double-blind, cross-over trial. J Clin Endocrinol Metab. 2006;91:1317–22.

    Article  PubMed  CAS  Google Scholar 

  24. Nielsen VE, Bonnema SJ, Boel-Jorgensen H, Grupe P, Hegedus L. Stimulation with 0.3 mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign non-toxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med 2006;166:1476–82.

    Article  PubMed  CAS  Google Scholar 

  25. Bachmann J, Kobe C, Bor S, Rahlff I, Dietlein M, Schicha H, et al. Radioiodine therapy for thyroid volume reduction of large goitres. Nucl Med Commun. 2009;30:466–71.

    Article  PubMed  Google Scholar 

  26. Cappelen T, Unhjem JF, Amundsen AL, Kravdal G, Følling I. Radiation exposure to family members of patients with thyrotoxicosis treated with iodine-131. Eur J Nucl Med Mol Imaging. 2006;33:81–6.

    Article  PubMed  CAS  Google Scholar 

  27. Koch W, Rosa F, Knesewitsch P, Hahn K. Guideline on radiation protection in medicine requires documentation of radioiodine therapy and follow-up: what are the benefits of an electronic database? Nuklearmedizin. 2005;44:49–55.

    PubMed  CAS  Google Scholar 

  28. Dillehay GL, Ellerbroek NA, Balon H, Brill DR, Grigsby PW, Macklis RM, et al.; American Society for Therapeutic Radiology and Oncology Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources. Int J Radiat Oncol Biol Phys. 2006;64:1299–307.

    PubMed  Google Scholar 

  29. International Commission on Radiological Protection. Release of patients after therapy with unsealed radionuclides. Ann ICRP. 2004;34:1–79. Erratum in: Ann ICRP 2004; 34(3-4): 281. Ann ICRP 2006; 36(4):77.

    Google Scholar 

  30. Royal College of Physicians of London. Radioiodine in themanagement of benignthyroid disease:clinical guidelines. London: RCP; 2007. http://www.rcplondon.ac.uk/pubs/contents/0621b67a-4880-4a1b-9942-57a666efee4a.pdf

  31. Dietlein M, Dressler J, Grünwald F, Leisner B, Moser E, Reiners C, et al. Guideline for radioiodine therapy for benign thyroid diseases (version 4). Nuklearmedizin. 2007;46:220–3.

    PubMed  CAS  Google Scholar 

  32. Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003;24:102–32.

    Article  PubMed  Google Scholar 

  33. Nieuwlaat WA, Huysmans DA, van den Bosch HC, Sweep CG, Ross HA, Corstens FH, et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab. 2003;88:3121–9.

    Article  PubMed  CAS  Google Scholar 

  34. Dietlein M, Dressler J, Eschner W, Lassman M, Leisner B, Reiners C, et al.; für die Deutsche Gesellschaft für Nuclearmedizin (DGN) und die Deutsche Gesellschaft für Medizinische Physik (DGMP) Procedure guideline for radioiodine test (version 3). Nuklearmedizin. 2007;46:198–202.

    PubMed  CAS  Google Scholar 

  35. Stabin MG, Brill AB. State of the art in nuclear medicine dose assessment. Semin Nucl Med. 2008;38:308–20.

    Article  PubMed  Google Scholar 

  36. Salvatori M, Luster M. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:821–8.

    Article  PubMed  Google Scholar 

  37. Kobe C, Eschner W, Wild M, Rahlff I, Sudbrock F, Schmidt M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of I-131? Nucl Med Commun. 2010;31:201–5.

    Article  PubMed  CAS  Google Scholar 

  38. Weetman AP. Radioiodine treatment for benign thyroid diseases. Clin Endocrinol. 2007;66:757–64.

    Article  CAS  Google Scholar 

  39. de Rooy A, Vandenbroucke JP, Smit JW, Stokkel MP, Dekkers OM. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol. 2009;161:771–7.

    Article  CAS  Google Scholar 

  40. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine in Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2003;88:978–83.

    Article  PubMed  CAS  Google Scholar 

  41. Boeleart K, Syed AA, Manji N, Sheppard MC, Holder RL, Gough SC, et al. Prediction of cure and risk of hypothyroidism in patients receiving I-131 for hyperthyroidism. Clin Endocrinol. 2009;70:129–38.

    Article  Google Scholar 

  42. Kobe C, Eschner W, Sudbrock F, Weber I, Marx K, Dietlein M, et al. Graves’ disease and radioiodine therapy: is success of ablation dependent on the achieved dose above 200 Gy? Nuklearmedizin. 2008;47:13–7.

    PubMed  CAS  Google Scholar 

  43. Sisson JC, Avram AM, Rubello D, Gross MD. Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design of science? Eur J Nucl Med Mol Imaging. 2007;34:1129–30.

    Article  PubMed  Google Scholar 

  44. Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves' disease is radioiodine. J Clin Endocrinol Metab. 2007;92:797–800.

    Article  PubMed  CAS  Google Scholar 

  45. Chao M, Jiawei X, Guoming W, Jianbin L, Wanxia L, Driedger A, et al. Radioiodine treatment for pediatric hyperthyroid Graves’ disease. Eur J Pediatr. 2009;168:1165–9.

    Article  PubMed  CAS  Google Scholar 

  46. Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population based cohort study. Lancet. 1999;353:2111–5.

    Article  PubMed  CAS  Google Scholar 

  47. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab. 1974;38:976–98.

    Article  PubMed  CAS  Google Scholar 

  48. Boice JD Jr. Radiation induced thyroid cancer – what’s new? J Natl Cancer Inst. 2005;97:703–5.

    Article  PubMed  Google Scholar 

  49. Hall P, Holm LE. Late consequences of radioiodine for diagnosis and therapy in Sweden. Thyroid. 1997;7:205–8.

    Article  PubMed  CAS  Google Scholar 

  50. Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch V, et al. Risk of thyroid cancer after exposure to I-131 in childhood. J Natl Cancer Inst. 2005;97:724–32.

    Article  PubMed  Google Scholar 

  51. Read Jr CH, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metabol. 2004;89:4229–33.

    Article  CAS  Google Scholar 

  52. Reiners C. Radioactivity and thyroid cancer. Hormones. 2009;8:185–92.

    PubMed  Google Scholar 

  53. Ron E, Doody MM, Becker DV, Harris BS 3rd, Hoffman DA, McConahey WM, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative thyrotoxicosis therapy follow-up study group. JAMA. 1998;280:347–55.

    Article  PubMed  CAS  Google Scholar 

  54. Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics. 2003;111:745–9.

    Article  PubMed  Google Scholar 

  55. Rivkees SA, Sklar C, Freemark M. Clinical review: the management of Graves’ disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab. 1998;83:3767–76.

    Article  PubMed  CAS  Google Scholar 

  56. Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab. 1997;82:1719–26.

    Article  PubMed  CAS  Google Scholar 

  57. Ma C, Kuang A, Xie J, Liu GJ. Radioiodine for pediatric Graves’ disease. John Wiley & Sons, Ltd, 2009. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD006294. doi:10.1002/14651858.CD006294.pub2

  58. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326:1733–8.

    Article  PubMed  CAS  Google Scholar 

  59. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338:73–8.

    Article  PubMed  CAS  Google Scholar 

  60. Hall P, Lundell G, Holm LE. Mortality in patients treated for hyperthyroidism with iodine-131. Acta Endocrinol (Copenh). 1993;128:230–4.

    CAS  Google Scholar 

  61. Lucignani G. Long-term risks in hyperthyroid patients treated with radioiodine: is there anything new? Eur J Nucl Med Mol Imaging. 2007;34:1504–9.

    Article  PubMed  Google Scholar 

  62. Dickman PW, Holm LE, Lundell G Jr, Hall P. Thyroid cancer risk after thyroid examination with I-131: a population-based cohort study in Sweden. Int J Cancer. 2003;106:580–7.

    Article  PubMed  CAS  Google Scholar 

  63. Sanyal D, Mukhhopadhyay P, Pandit K, Chatterjee J, Raychaudhuri M, Mukherjee S, et al. Early treatment with low fixed dose (5 mCi) radioiodine therapy is effective in Indian subjects with Graves’ disease. J Indian Med Assoc. 2008;106:360–361, 372.

    PubMed  Google Scholar 

  64. Canadas V, Vilar L, Moura E, Brito A, Castellar E. Evaluation of radioiodine therapy with fixed doses of 10 and 15 mCi in patients with Graves’ disease. Arq Bras Endocrinol Metab. 2007;51:1069–76.

    Article  Google Scholar 

  65. Collier A, Gosh S, Hair M, Malik I, McGarvie J. Comparison of two fixed activities of radioiodine therapy (370 vs. 555 MBq) in patients with Graves’ disease. Hormones (Athens). 2009;8:273–8.

    Google Scholar 

  66. Jensen BE, Bonnema SJ, Hegedues L. Glucocorticoids do not influence the effect of radioiodine therapy in Graves’ disease. Eur J Endocrinol. 2005;153:15–21.

    Article  PubMed  CAS  Google Scholar 

  67. Dunkelmann S, Kuenster H, Nabavi E, Rohde B, Groth P, Schuemichen C. Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves’ disease. Eur J Nucl Med Mol Imaging. 2007;34:228–36.

    Article  PubMed  CAS  Google Scholar 

  68. Kubota S, Ohye H, Yano G, Nishihara E, Kudo T, Ito M, et al. Two-day thioamide withdrawal prior to radioiodine uptake sufficiently increases uptake and does not exacerbate hyperthyroidism compared to 7-day withdrawal in Graves’ disease. Endocrine J. 2006;53:603–7.

    Article  CAS  Google Scholar 

  69. Walter MA, Crist-Crain M, Schindler C, Mueller-Brand J, Mueller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging. 2006;33:730–7.

    Article  PubMed  CAS  Google Scholar 

  70. Reinhardt MJ, Brink I, Joe AY, von Mallek D, Ezziddin S, Palmedo H, et al. Radioiodine therapy in Graves’ disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med. 2002;29:1118–24.

    Article  CAS  Google Scholar 

  71. Dunkelmann S, Neumann V, Staub U, Groth P, Kuenstner H, Schuemichen C. Results of a risk adapted and functional radioiodine therapy in Graves’ disease. Nuklearmedizin. 2005;44:238–42.

    PubMed  CAS  Google Scholar 

  72. Reinhardt MJ, Joe A, von Mallek D, Zimmerlin M, Manka-Waluch A, Palmedo H, et al. Dose selection for radioiodine therapy of borderline hyperthyroid patients with multifocal and disseminated autonomy on the basis of 99mTc-pertechnetate thyroid uptake. Eur J Nucl Med Mol Imaging. 2002;29:480–5.

    Article  PubMed  CAS  Google Scholar 

  73. Dunkelmann S, Endlicher D, Prillwitz A, Rudolph F, Groth P, Schuemichen C. Results of a TcTUs-optimized radioiodine therapy of multifocal and disseminated functional thyroid autonomy. Nuklearmedizin. 1999;38:131–9.

    PubMed  CAS  Google Scholar 

  74. Reiners C, Schneider P. Radioiodine therapy of thyroid autonomy. Eur J Nucl Med. 2002;29 Suppl 2:S471–8.

    Article  CAS  Google Scholar 

  75. Reinhardt M, Kim B, Wissmeyer M, Juengling F, Brockmann H, von Mallek D, et al. Dose selection for radioiodine therapy of borderline hyperthyroid patients according to thyroid uptake of 99mTc-pertechnetate: applicability to unifocal thyroid autonomy? Eur J Nucl Med Mol Imaging. 2006;33:608–12.

    Article  PubMed  CAS  Google Scholar 

  76. Manders JMB, Corstens FHM. Radioiodine therapy of euthyroid multinodular goitres. Eur J Nucl Med. 2002;29(Suppl2):S466–70.

    Article  CAS  Google Scholar 

  77. Cohen O, Ilany J, Hoffman C, Olchovsky D, Karasik A, Goshen E, et al. Low dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients. Eur J Endocrinol. 2006;154:243–52.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX Amsterdam, The Netherlands

    Marcel P. M. Stokkel

  2. Department of Nuclear Medicine and Endocrine Oncology, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, 44100, Gliwice, Poland

    Daria Handkiewicz Junak

  3. Department of Nuclear Medicine, University of Würzburg, 97080, Würzburg, Germany

    Michael Lassmann

  4. Department of Nuclear Medicine, University of Cologne, 50937, Cologne, Germany

    Markus Dietlein

  5. Department of Nuclear Medicine, University of Ulm, 89081, Ulm, Germany

    Markus Luster

Authors
  1. Marcel P. M. Stokkel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daria Handkiewicz Junak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Lassmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Markus Dietlein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Markus Luster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcel P. M. Stokkel.

Additional information

Disclaimer

These guidelines summarize the views of the Radionuclide Therapy Committee of the EANM and reflect recommendations for which the EANM cannot be held responsible. The recommendations should be taken in the context of good practice of nuclear medicine and do not substitute for national and international legal or regulatory provisions.

The EANM has approved guidelines to promote the cost-effective use of high-quality nuclear medicine procedures. These generic recommendations cannot be rigidly applied to all patients in all practice settings. The guidelines should not be deemed inclusive of all proper procedures or exclusive of other procedures reasonably directed to obtaining the same results. Advances in medicine occur at a rapid rate. The data of guidelines should always be considered in determining their current applicability.

The Dosimetry Committee was involved in the writing of these guidelines, and they have been reviewed by the Oncology Committee, the Paediatrics Committee and the Physics Committee. The guidelines have been brought to the attention of the National Societies of Nuclear Medicine.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stokkel, M.P.M., Handkiewicz Junak, D., Lassmann, M. et al. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging 37, 2218–2228 (2010). https://doi.org/10.1007/s00259-010-1536-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-010-1536-8

Keywords

Search

Navigation